US HB573 | 2009-2010 | 111th Congress

Status

Sponsorship: Bipartisan Bill
Status: Introduced on January 15 2009 - 25% progression, died in committee
Action: 2009-01-16 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the exclusivity period granted to the generic manufacturer.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs.

Sponsors


History

DateChamberAction
2009-01-16 Referred to the Subcommittee on Health.
2009-01-15 Referred to the House Committee on Energy and Commerce.

Subjects


US Congress State Sources


feedback